{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:09:29Z","timestamp":1786990169782,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4020153"],"award-info":[{"award-number":["4020153"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.heliyon.2025.e42244","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:27:36Z","timestamp":1737660456000},"page":"e42244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A meta-analytic evaluation of the efficacy and safety of levetiracetam for treating myoclonic seizures"],"prefix":"10.1016","volume":"11","author":[{"given":"Sara","family":"Najafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaddeseh Sadat","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Sadeghnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2025.e42244_bib1","first-page":"1","article-title":"Definition and classification of myoclonus","volume":"43","author":"Fahn","year":"1986","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1528-1157.44.s11.4.x","article-title":"Classification of the myoclonic epilepsies","volume":"44","author":"Leppik","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib3","series-title":"Neurology","first-page":"196","article-title":"The nosology and pathophysiology of myoclonus, Movement disorders","volume":"vol. 2","author":"Cd","year":"1982"},{"key":"10.1016\/j.heliyon.2025.e42244_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.seizure.2010.12.017","article-title":"A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target","volume":"20","author":"Chhun","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-510X(00)00496-2","article-title":"Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients","volume":"184","author":"Montalenti","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.heliyon.2025.e42244_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/epi4.12321","article-title":"Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients","volume":"4","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.heliyon.2025.e42244_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40263-018-00602-2","article-title":"Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential","volume":"33","author":"Serafini","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.heliyon.2025.e42244_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11940-011-0131-z","article-title":"Treatment options in juvenile myoclonic epilepsy","volume":"13","author":"Mantoan","year":"2011","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/epi.16450","article-title":"Repurposed molecules for antiepileptogenesis: missing an opportunity to prevent epilepsy?","volume":"61","author":"Klein","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/ph15040475","article-title":"Levetiracetam mechanisms of action: from molecules to systems","volume":"15","author":"Contreras-Garc\u00eda","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2025.e42244_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/brainsci11050531","article-title":"Synaptic vesicle protein 2a expression in glutamatergic terminals is associated with the response to levetiracetam treatment","volume":"11","author":"Contreras-Garc\u00eda","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.heliyon.2025.e42244_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26650","article-title":"Differential effects of antiseizure medications on neurogenesis: evidence from cells to animals","volume":"10","author":"Alavi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2025.e42244_bib14","series-title":"Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety","author":"Subramonian","year":"2021"},{"key":"10.1016\/j.heliyon.2025.e42244_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ern.10.3","article-title":"Levetiracetam: a comprehensive review","volume":"10","author":"Crepeau","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.heliyon.2025.e42244_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12028-021-01296-z","article-title":"Levetiracetam for seizure prophylaxis in neurocritical care: a systematic review and meta-analysis","volume":"36","author":"Fang","year":"2022","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.heliyon.2025.e42244_bib17","first-page":"617","article-title":"Efficacy of levetiracetam, lamotrigine and sodium valproate on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy: a double blind randomized clinical trial","volume":"13","author":"Daneshyar","year":"2022","journal-title":"Caspian Journal of Internal Medicine"},{"key":"10.1016\/j.heliyon.2025.e42244_bib18","doi-asserted-by":"crossref","DOI":"10.17795\/jjhr-21875","article-title":"Comparison of levetiracetam with sodium valproate in controlling seizure in patients suffering from juvenile myoclonic epilepsy","volume":"5","author":"Kashipazha","year":"2014","journal-title":"Jentashapir J Cell Mol Biol"},{"key":"10.1016\/j.heliyon.2025.e42244_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12028-009-9185-0","article-title":"Safety and efficacy of levetiracetam for critically ill patients with seizures","volume":"11","author":"Nau","year":"2009","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.heliyon.2025.e42244_bib20","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.xphs.2023.03.025","article-title":"Development and validation of physiologically based pharmacokinetic model of levetiracetam to predict exposure and dose optimization in pediatrics","volume":"112","author":"Shao","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.heliyon.2025.e42244_bib21","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","author":"Brunton","year":"2018"},{"key":"10.1016\/j.heliyon.2025.e42244_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.seizure.2003.06.001","article-title":"Levetiracetam as add-on therapy in generalised epilepsies","volume":"13","author":"Kumar","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106214","article-title":"Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial","volume":"157","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib26","first-page":"1","article-title":"Levetiracetam add\u2010on for drug\u2010resistant focal epilepsy","volume":"6","author":"Mbizvo","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.heliyon.2025.e42244_bib27","first-page":"1","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta\u2010analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database. Syst. Rev."},{"key":"10.1016\/j.heliyon.2025.e42244_bib28","first-page":"1","article-title":"Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes","volume":"9","author":"Tan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.heliyon.2025.e42244_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JPN-2011-0461","article-title":"Lack of efficacy of levetiracetam and worsening of epileptic negative myoclonus","volume":"9","author":"Karkare","year":"2011","journal-title":"J. Pediatr. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.seizure.2012.08.008","article-title":"Levetiracetam-associated aggravation of myoclonic seizure in children","volume":"21","author":"Liu","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-015-0330-y","article-title":"Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy","volume":"15","author":"Makke","year":"2015","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.heliyon.2025.e42244_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jpainsymman.2018.07.012","article-title":"Levetiracetam","volume":"56","author":"Howard","year":"2018","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.heliyon.2025.e42244_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","article-title":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies","volume":"85","author":"Rosenfeld","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib34","volume":"vol. 372","author":"Page","year":"2021"},{"key":"10.1016\/j.heliyon.2025.e42244_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11011-021-00888-0","article-title":"Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer's disease","volume":"37","author":"Alavi","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.heliyon.2025.e42244_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119923","article-title":"Levetiracetam promoted rat embryonic neurogenesis via NMDA receptor-mediated mechanism in vitro","volume":"284","author":"Alavi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2025.e42244_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","article-title":"Levetiracetam treatment of idiopathic generalised epilepsy","volume":"12","author":"Krauss","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1212\/WNL.57.6.1112","article-title":"A pilot tolerability and efficacy study of Levetiracetam in patients with chronic myoclonus","volume":"57","author":"Frucht","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.20530","article-title":"Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study","volume":"20","author":"Striano","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2007.01524.x","article-title":"A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome)","volume":"49","author":"Striano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib41","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.4103\/0366-6999.243568","article-title":"Antimyoclonic effect of levetiracetam and clonazepam combined treatment on myoclonic epilepsy with ragged-red fiber syndrome with m.8344A>G mutation","volume":"131","author":"Su","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.heliyon.2025.e42244_bib42","volume":"vol. 115","author":"Milano","year":"2021"},{"key":"10.1016\/j.heliyon.2025.e42244_bib43","first-page":"531","article-title":"Effect of levetiracetam on resistant juvenile myoclonic epilepsy","volume":"11","author":"Greenhill","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2007.07.001","article-title":"Levetiracetam monotherapy in juvenile myoclonic epilepsy","volume":"17","author":"Sharpe","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib46","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNF.0000000000000177","article-title":"Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy","volume":"39","author":"Sala-Padr\u00f3","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib48","first-page":"77","article-title":"Evaluation of the efficacy and tolerability of levetiracetam as add-on therapy in intractable epilepsy of children","volume":"16","author":"Razieh","year":"2022","journal-title":"Iran. J. Child Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.seizure.2005.08.002","article-title":"Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany","volume":"14","author":"Opp","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1059131102001723","article-title":"A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy","volume":"12","author":"Nakken","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib51","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/08830738040190120601","article-title":"Retrospective study of the use of levetiracetam in childhood seizure disorders","volume":"19","author":"Koukkari","year":"2004","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.13389","article-title":"Levetiracetam as first-line monotherapy for idiopathic generalized epilepsy in women","volume":"143","author":"Ballv\u00e9","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.heliyon.2025.e42244_bib53","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","article-title":"An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy","volume":"69","author":"Striano","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","article-title":"Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.seizure.2016.01.017","article-title":"The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population","volume":"36","author":"Tekg\u00fcl","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura","year":"2005","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eplepsyres.2009.10.005","article-title":"Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome","volume":"88","author":"Specchio","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.pediatrneurol.2014.06.004","article-title":"Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome","volume":"51","author":"Kim","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib60","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1684\/j.1950-6945.2003.tb00028.x","article-title":"Long\u2010term experience with levetiracetam","volume":"5","author":"Abou\u2010Khalil","year":"2003","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib61","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P2.059","article-title":"Levetiracetam monotherapy is as effective as valproate in newly diagnosed cases with juvenile myoclonic epilepsy (JME)(P2. 059)","volume":"86","author":"Alhamrani","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib62","first-page":"205","article-title":"Seizure control with levetiracetam in juvenile myoclonic epilepsies","volume":"46","author":"Andermann","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2004.03.006","article-title":"Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy","volume":"59","author":"Coppola","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib64","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/01.WNL.0000110193.78872.DD","article-title":"Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients","volume":"62","author":"Crest","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2025.e42244_bib65","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pediatrneurol.2003.09.007","article-title":"Levetiracetam in the treatment of Lennox-Gastaut syndrome","volume":"30","author":"De Los Reyes","year":"2004","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1528-1167.2011.03300.x","article-title":"Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open\u2010label, noncomparative, multicenter, long\u2010term follow\u2010up study","volume":"53","author":"Delanty","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.seizure.2005.02.004","article-title":"Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy","volume":"14","author":"Grosso","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.seizure.2007.02.004","article-title":"Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy","volume":"16","author":"Grosso","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib69","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1059-1311(03)00154-7","article-title":"Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities","volume":"13","author":"Huber","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/1817-1745.97614","article-title":"The efficacy and side effects of levetiracetam on refractory epilepsy in children","volume":"7","author":"Incecik","year":"2012","journal-title":"J. Pediatr. Neurosci."},{"key":"10.1016\/j.heliyon.2025.e42244_bib71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2013.0599","article-title":"The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre","volume":"15","author":"Kang","year":"2013","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1090-3798(03)00041-2","article-title":"Effect of levetiracetam in refractory childhood epilepsy syndromes","volume":"7","author":"Lagae","year":"2003","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2019.05.021","article-title":"Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"98","author":"Landmark","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.heliyon.2025.e42244_bib74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pediatrneurol.2009.08.002","article-title":"Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy","volume":"42","author":"Lee","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib75","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/0883073809342489","article-title":"Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy","volume":"25","author":"Li","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.heliyon.2025.e42244_bib76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.parkreldis.2004.07.010","article-title":"Limited efficacy of levetiracetam on myoclonus of different etiologies","volume":"11","author":"Lim","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib77","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.0013-9580.2004.56902.x","article-title":"Antimyoclonic effect of levetiracetam in 13 patients with Unverricht\u2013Lundborg disease: clinical observations","volume":"45","author":"Magaudda","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.heliyon.2025.e42244_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2004.02.006","article-title":"Levetiracetam in refractory epilepsy: a prospective observational study","volume":"14","author":"Mohanraj","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1684\/epd.2014.0654","article-title":"Seizure control in Unverricht\u2010Lundborg disease: a single\u2010centre study","volume":"16","author":"Roivainen","year":"2014","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.heliyon.2025.e42244_bib80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.heliyon.2025.e42244_bib81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","article-title":"Levetiracetam monotherapy\u2014outcomes from an epilepsy clinic","volume":"20","author":"Stephen","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.heliyon.2025.e42244_bib82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2010.06.002","article-title":"Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial","volume":"90","author":"Tonekaboni","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.heliyon.2025.e42244_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107745","article-title":"Levetiracetam monotherapy in children with epilepsy: experience from a tertiary pediatric neurology center","volume":"116","author":"Y\u0131ld\u0131r\u0131m","year":"2021","journal-title":"Epilepsy Behav."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025006243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025006243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:03:18Z","timestamp":1775739798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025006243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2405844025006243"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42244","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analytic evaluation of the efficacy and safety of levetiracetam for treating myoclonic seizures","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e42244"}}